Witte Jan De (Director) sold ~$102K of ResMed|
Planned saleWant the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RMD · NYSE · Health Care Equipment
$236.88−5.73 (−2.36%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day, not a live quote
ResMed| (RMD) · oqro.io/stocks/RMD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
62 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Witte Jan De (Director) sold ~$102K of ResMed|
Planned saleDe Witte Jan (Director) plans to sell ~$102K of ResMed|
Planned, from payMichael J. Farrell (Chairman and CEO) sold ~$1.18M of ResMed|
Planned saleMichael J. Farrell (Officer) plans to sell ~$1.18M of ResMed|
Planned, from payMichael J Rider (Global General Counsel) sold ~$102K of ResMed|
Planned saleMichael J. Rider (Officer) plans to sell ~$102K of ResMed|
Planned, from payMichael J. Farrell (Chairman and CEO) sold ~$1.13M of ResMed|
Planned saleMichael J. Farrell (Officer) plans to sell ~$1.13M of ResMed|
Planned, from payMichael J. Farrell (Chairman and CEO) sold ~$1.11M of ResMed|
Planned saleMichael J. Farrell (Officer) plans to sell ~$1.13M of ResMed|
Planned, from payPeter C Farrell (Director) sold ~$228K of ResMed|
Planned salePeter C Farrell (Director) plans to sell ~$228K of ResMed|
Planned, from payMichael J. Farrell (Chairman and CEO) sold ~$1.03M of ResMed|
Planned salePeter C Farrell (Director) sold ~$1.8M of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.09M of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$968K of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.04M of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.13M of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$224K of ResMed|
Planned salePeter C Farrell (Director) sold ~$450K of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.25M of ResMed|
Planned salePeter C Farrell (Director) sold ~$520K of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$254K of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.37M of ResMed|
Planned salePeter C Farrell (Director) sold ~$503K of ResMed|
Planned saleMichael J Rider (Global General Counsel) sold ~$13K of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$257K of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.24M of ResMed|
Planned salePeter C Farrell (Director) sold ~$498K of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$242K of ResMed|
Planned saleMichael J Rider (Global General Counsel) sold ~$12K of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$1.25M of ResMed|
Planned salePeter C Farrell (Director) sold ~$503K of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$244K of ResMed|
Planned saleMichael J Rider (Global General Counsel) sold ~$12K of ResMed|
Planned saleWitte Jan De (Director) sold ~$524K of ResMed|
Planned salePeter C Farrell (Director) sold ~$504K of ResMed|
Planned saleWitte Jan De (Director) sold ~$122K of ResMed|
Planned saleMichael J. Farrell (Chairman and CEO) sold ~$2M of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$743K of ResMed|
Planned sale0 open-market purchases and 13 open-market sales by insiders of RMD between Mar 31, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 29, 2026. The data provider lists the next release for Jan 27, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Oct 29, 2026 | 2 sales | None | 1 sale |
| Aug 6, 2026 | 2 sales | None | 2 sales |
| Jul 7, 2026 | 1 sale | 1 sale | 1 sale |
| Apr 30, 2026 | 3 sales | None | 1 sale |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies